Full-Time

Master Data Governance Sr. Specialist

Posted on 9/19/2024

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Senior

Bridgewater Township, NJ, USA

Category
Data Management
Data Engineering
Data & Analytics
Required Skills
Agile
SAP Products
Data Analysis
Requirements
  • Bachelor's degree in IT, Computer Sciences, Supply Chain Management or a related Data & Analytics field
  • Minimum of 5 years' experience in SAP MDG - Material Master, Planning, Procurement, Vendors Data Objects, Customer, Vendor, etc.
  • Minimum of +3 years developing and implementing MDM solutions and data governance processes, including hands-on design and configuration
  • Experience with leading business process reengineering and business process assessment
  • Exceptional communication and interpersonal skills, with the aptitude to effectively engage and influence stakeholders at all levels
  • Demonstrated capability to lead and manage cross-functional teams, fostering collaboration, and achieving high-performance outcomes; demonstrated ability to lead and manage change initiatives while driving organizational transformation
  • Advanced technical knowledge of SAP Master Data specifically in at least three (3) of the Production, Materials Management, Quality and/or Extended Warehouse Management SAP modules
Responsibilities
  • Design, implement and deploy a global standard and data creation workflow process that supports GMS business activities, and in line with IT’s MDG template
  • Utilize extensive master data expertise to demonstrate a profound understanding of SAP MDG Materials, BOM, Recipes, MRP, MPS, Work Centers, Batch Management, Quality Inspection, Costing among others
  • Collaborate with business stakeholders, collaboration partners, and business process owners to conduct comprehensive analysis on all GMS material management aspects addressing data creation, data quality, governance needs and dealing with all data interconnectivity with other systems
  • Build and drive plans to improve data practices for operational, reporting and analysis needs – Inclusive of development of processes, control and best business practices around data management
  • Build organization understanding of data lifecycles from creation to end use, working with subject matter experts in various business functions, operations, and IT teams
  • Create and maintain process maps, data objects and user guides, to ensure a comprehensive knowledge base
  • Manage and support all site-specific projects with respect to new product launches, alternate material sources, alternate BOM/recipes, etc. and collaborate on required change control deliverables where applicable
  • Provide expert-level support for SAP MDG modules, addressing functional issues, incidents, and change requests. Work closely with the support team to prioritize and resolve tickets efficiently
  • Oversee change management procedures, including business engagement, impact analysis, documentation review and approval, user testing reviews, ensuring smooth and controlled changes to minimize risks and disruptions associated with GMS activities
  • Identify opportunities for process improvement and optimization within the MDG areas, leveraging SAP functionalities and best practices to drive efficiency and effectiveness while maintaining regulatory compliance
  • Embrace and promote Agile principles and values within the team and projects, fostering a culture of continuous improvement and iterative development
  • Create an environment that encourages open communication, teamwork, and innovation, contributing to a positive and collaborative work culture

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $150M investment in Belgium facility shows commitment to expanding production capabilities.
  • Alan Bash's appointment strengthens leadership in CAR-T therapy market.
  • New R&D facility in Philadelphia focuses on next-generation cell therapies.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact market share.
  • Collaboration with Multiply Labs may face challenges in scaling up production.
  • Expansion of R&D facilities requires significant investment, potentially straining resources.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Fierce Pharma
Mar 12th, 2025
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.

The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

INACTIVE